Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seleniun/cancer claim

This article was originally published in The Tan Sheet

Executive Summary

Supplement maker Wellness Lifestyles d/b/a American Longevity seeks FDA approval of health claims stating selenium "may reduce the risk of certain cancers" and "may produce anticarcinogenic effects in the body." Petition filed July 10 notes claims "do not identify specific intake quantities for selenium," although studies have shown risk reduction with 50-200 mcg/day. Adult daily intake below 900 mcg "is unlikely to cause adverse reactions," Wellness adds. Petition cites six human clinical trials (three in China, and one each in U.S., India, Italy) on selenium supplementation and cancer incidence. Firm is represented by Emord & Associates (Washington, D.C.), which filed a health claim petition for phosphatidylserine and cognitive dysfunction/dementia in April (1"The Tan Sheet" May 6, 2002, p. 10)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel